论文部分内容阅读
目的观察玻璃体注射雷珠单抗治疗老年黄斑变性黄斑水肿(AMD-ME)与视网膜静脉阻塞性黄斑水肿(RVO-ME)的短期临床效果。设计回顾性病例系列。研究对象2015年10月至2016年7月确诊为AMD-ME及RVO-ME的患者共30例(30眼),各15例(15眼)。方法患眼接受玻璃体注射雷珠单抗(0.5 mg/0.05 ml)治疗,采用1+PRN的注射方法,比较治疗前和治疗后1天、1个月最佳矫正视力(BCVA)、眼压(IOP)、黄斑中心凹视网膜厚度(CMT)、注射后消除的水肿高度,评价每次随访时检查结果。主要指标BCVA、CMT、消除的水肿高度、IOP。结果 AMD-ME组及RVO-ME组注射雷珠单抗后1天、1个月的BCVA均较术前提高(P=0.000、0.000)。AMD-ME组及RVO-ME组每次治疗前和治疗后1个月CMT厚度均降低(P=0.000、0.000)。治疗过程中患者眼压与治疗前比较并无明显变化(P=0.096、0.066、0.213、0.088、0.240、0.337)。结论玻璃体注射雷珠单抗治疗AMD-ME及RVO-ME在短期内均可减轻黄斑水肿和改善视力,两者治疗效果无明显差异。
Objective To observe the short-term clinical efficacy of vitreous injection of ranibizumab in the treatment of AMD-ME and RVO-ME. Design retrospective case series. Thirty patients (30 eyes) and 15 eyes (15 eyes) were diagnosed with AMD-ME and RVO-ME from October 2015 to July 2016 respectively. Methods The patients were treated with vitreous injection of ranibizumab (0.5 mg / 0.05 ml) and 1 + PRN injection. The best corrected visual acuity (BCVA) and intraocular pressure (IOP) were measured before and 1 day and 1 month after treatment. IOP), macular foveal retinal thickness (CMT), edema height eliminated after injection, and the results of each visit were evaluated. The main indicators of BCVA, CMT, the elimination of edema height, IOP. Results The BCVA at 1 day and 1 month after injection of ranibizumab in AMD-ME group and RVO-ME group was significantly higher than that before operation (P = 0.000, 0.000). The thickness of CMT in both AMD-ME and RVO-ME groups decreased before and after 1 month (P = 0.000, 0.000). The intraocular pressure of patients during treatment did not change significantly compared with that before treatment (P = 0.096,0.066,0.213,0.088,0.240,0.337). Conclusion Intravitreal injection of ranibizumab in the treatment of AMD-ME and RVO-ME can both reduce macular edema and improve visual acuity in the short term. There is no significant difference between the two treatments.